Answers are grounded in this paper and cite their sources.
This study propose that JAK-inhibitors perhaps provide advantageous effects on Covid-19 outcomes. JAK-inhibitors may be given during 1-2 weeks of disease to optimize its beneficial effects in halting the exaggerated immune response.
No takes yet. Share an insight, caveat, or question.
Limen et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: